Philip Ansumana Hull

Philip Ansumana Hull is an experienced biomarker and immuno-oncology expert currently serving as Associate Director Clinical Biomarkers at Gilead Sciences since April 2022, where responsibilities include pharmacodynamics and predictive biomarker work for early oncology trials. Previously, Philip held various roles at Bristol Myers Squibb from August 2018 to March 2022, including Senior Scientist and Research Investigator, focusing on early clinical-stage immuno-oncology assets, in vitro and in vivo research, target validation, and employee resource group initiatives. Academic credentials include a PhD in Biology with a focus on Immunology from WWU and the Gladstone Institute, along with multiple post-graduate degrees in Biotechnology and Molecular Biology. Prior research experiences encompass immune aging, HIV infection studies, and contributions to diagnostic tool development across several institutions.